CA2207667A1 - Embolizing system - Google Patents
Embolizing systemInfo
- Publication number
- CA2207667A1 CA2207667A1 CA002207667A CA2207667A CA2207667A1 CA 2207667 A1 CA2207667 A1 CA 2207667A1 CA 002207667 A CA002207667 A CA 002207667A CA 2207667 A CA2207667 A CA 2207667A CA 2207667 A1 CA2207667 A1 CA 2207667A1
- Authority
- CA
- Canada
- Prior art keywords
- wire
- elongate member
- occlusion
- particles
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
Abstract
An embolizing system (18) includes a catheter (20) having a lumen, an elongate member (22), insertable within the lumen of the catheter (20), and an occlusion particle (24). The occlusion particle (24) has a receiving passageway (32) therein for receiving the elongate member (22) so the elongate member (22) guides movement of the occlusion particle (24).
Description
W O 96/22736 PC~rAUS96/00221 E~DBO LIZ IN G S YSTEM
BACKGROUND OF THE INVENTION
The present invention relates to an embolization system to block flow through a selected portion of a lumen. More particularly, the present invention relates to a system for introducing occlusion particles into the lumen of a blood vessel.
Embolization techniques are currently used to treat a variety of vascular and non-vascular diseases.
Such diseases include arteriovenous malformations (AVMs), aneurysms, arteriovenous fistulas, and tumors.
There are currently three basic types of embolization systems in use. Those systems include embolic liquids, solid or solid-type agents, and particles.
Embolic liquids include glues, (polymerizing agents), alcohols, and precipitating agents. Typical examples of embolic liquids are n-butylcyanoacrylate (n-BCA), ethyl alcohol and a precipitating agent sold by Ethicon of Germany under the tradename Ethibloc. The glues used as embolic liquids typically act to polymerize and harden in the vessel, thereby blocking or occluding the vessel into which they are introduced.
The alcohol or alcohol derivatives cause tissue damage to the vessel with resulting thrombus formation for occlusion. Precipitating agents typically include a precipitating agent which is dissolved in infusion solution, but insoluble in a blood environment. When the infusion solution is introduced into the vessel, the precipitating agent precipitates out to cause occlusion.
Embolic liquids currently suffer from a number of disadvantages. One disadvantage is that the liquids lack radiopacity. This makes it difficult to monitor the administration of the embolic liquids. Another disadvantage is that the release of embolic liquids into W096/22736 PCT~S96/00221 the vessel to be occluded is difficult to control. The liquids must be released upstream of the site at which eventual occlusion is desired. Blood flow carries the embolizing li~uid through the lumen of the vessel, and it is difficult to control the release of a proper amount of occlusive liquid into the vessel to insure that occlusion occurs at the desired site in the vessel.
Solid agents, when used in an embolization system, conventionally include occluding articles which are more discrete in nature than embolic liquids. Such articles have typically been formed of suture material or coils which are introduced into the vessel. The suture material (often silk), once released, assumes a convoluted shape within the vessel to cause thrombus formation and occlusion. A suture material occlusion system is discussed in the ~itchart et al. U.S. Patent 4,994,069 issued February 19, 1991. Coils, or coil assemblies, used as solid occlusion agents are shown in the Sepetka U.S. Patent 5,234,437 issued August 10, 1993. The coils occlude the desired site in the vessel by posing a physical barrier to blood flow. This promotes thrombus formation at the desired site, which eventually occludes the vessel.
However, solid agents also suffer from a number of disadvantages. First, solid agents conventionally depend on thrombus formation in order to accomplish complete occlusion. However, if anti-coagulant agents are introduced into the bloodstream during surgery, the anticoagulant can substantially prevent thrombus formation thereby minimizing the occlusive effect of the solid agent. Additionally, the bodies~ natural clot dissolving factors can cause recanalization. Further, when the solid agent is a coil, it is either an insertion coil or a detachable W096/22736 PCT~S96/00221 coil. Insertion coils are introduced into the vessel by injection, or by being pushed through a base catheter.
Once introduced into the vessel, they can become irretrievable and accurate delivery is difficult to control. When the coil is detachable, it must be particularly sized to fit the lumen of the vessel at the desired occlusion site. However, the size of the lumen of the vessel is difficult to predict. Therefore, it is not uncommon for the treating physician to move the solid agent (detachable coil) to the occlusion site only to find out that the dimensions of the detachable coil are inappropriate to the occlusion site in the vessel.
This requires the physician to remove essentially the entire coil system and to re-insert the system with a different size detachable coil. It may be necessary to repeat this process a number of times before the properly sized solid agent is finally inserted in the lumen. Also, when removing an improperly sized detachable coil, it is not uncommon for the coil to engage the base catheter and unravel or unwind. Such a system is time consuming and inefficient.
A third conventional embolization system utilizes what are known as embolizing particles or occlusion particles. Embolizing particles are typically smaller than solid occlusion agents and are suspended in solution. The solution is injected into the lumen to be occluded through a catheter. Typical embolization particles are made of polyvinylalcohol (PVA). The polyvinylalcohol particles are formed of a ground block of material which is put through a series of sieves to segregate the particles into various size categories.
The particles are suspended in solution and injected into the vessel through a delivery catheter.
W O 96/22736 P(~rrUS96/00221 However, conventional embolizing particles also suffer from a number of disadvantages. For example, in conventional systems, the particles cannot be easily retrieved once they are injected into the vessel. In addition, it is very difficult to control precisely how much of the injectate is delivered.
Further, typical PVA particles are in suspension and are therefore not typically well aligned as they travel through the catheter. Therefore, they can wedge together and substantially block the delivery catheter.
This requires the treating physician to either remove the entire system, including the delivery catheter, and replace it with another system, or to take extra time to remove the blockage from the delivery catheter. Another major problem associated with injecting PVA particles to occlude a vessel is referred to as reflux. Essentially, as PVA is injected into the vessel, and as the vessel begins to close, the distal flow at the occlusion site becomes smaller. Therefore, less injectate is needed at the occlusion site. If too much solution is injected, and the distal flow cannot accommodate the extra injectate, then the flow becomes proximal and can occlude a lumen of a normal vessel at a proximal site.
This problem essentially arises from the difficulty in controlling the amount of PVA particles injected into the vessel.
SU~ ARY OF THE IN VEN TION
An embolization system includes a catheter having a lumen. An elongate member is insertable within the lumen of the catheter. An occlusion particle has a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle through the lumen of the catheter and into a vessel.
W096l22736 PCT~S96/00221 BRIEF DESCRIPTION OF THE DRAWINGS
FIGs. 1, lA and lB illustrate one common problem with prior art embolization systems.
FIG. 2 is a cross-sectional view of an embolization system according to the present invention.
FIG. 3 is a cross-sectional view of the embolization system shown in FIG. 2, illustrating delivery of an occlusion particle into a vessel.
FIG. 4 is an enlarged and more detailed cross-section of the embolization system shown in FIGS. 2 and3.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
FIGS. 1, lA and lB illustrate a common problem with polyvinylalcohol (PVA) injection type embolization systems. FIG. 1 shows a delivery catheter 10 residing in a vessel 11 and having a distal end 13. Catheter 10 is carrying a PVA solution, or injectate, which includes a plurality of PVA particles 12. While PVA particles 12 are not typically perfect spheres, they are illustrated as spheres for the sake of simplicity in FIG. 1. In operation, delivery catheter 10 is typically manipulated through vessel 11 so distal end 13 is proximate a desired occlusion site 14. When distal end 13 of delivery catheter 10 reaches occlusion site 14, the solution carrying PVA particles 12 is injected into the delivery catheter 10 and delivered to occlusion site 14.
It is difficult to predict the precise amount (both size of particles and number of particles required) of injectate needed to occlude vessel 11 at site 14. Also, it is difficult to precisely control the amount of injectate delivered to site 14. This results in a wide variety of problems, most of which were mentioned in the Background of the Invention portion of the present specification.
W 096/22736 PCTnUS96/00221 In addition, PVA-type occlusion can also suffer from one of the problems commonly associated with discrete or solid-type occlusion devices. When the PVA
particles 12 are delivered to site 14, thrombus formation can cause occlusion. However, during surgery, anticoagulant therapy may be administered. This therapy can substantially prevent thrombus formation. Thus, the treating physician must inject more solution carrying PVA particles 12. Due to the difficulty in controlling delivery of an accurate amount (size and number of particles) of the solution, the need to deliver extra solution exacerbates the problem of potential reflux in vessel 11. Further, the body has natural clot dissolving factors which can begin to act on the thrombus. This can cause the thrombus at site 14 to dissolve over time.
In accessing site 14, catheter 10 must commonly make a number of bends. FIG. lA, taken along section lines lA-lA in FIG. 1, shows the conventional cross-section of catheter 10 as being circular.
However, FIG. lB is taken along section lines lB-lB of FIG. 1 at a point where catheter 10 bends to access site 14. The cross-section at the bent portion of catheter 10 is oval shaped. Since particles 12 are simply mixed in solution and injected through catheter 10, they are not typically aligned along a longitudinal axis of catheter 10. As the particles reach the oval cross-section of catheter 10, it is not uncommon for the particles to lodge against one another and the walls of catheter 10 to obstruct flow of the solution through catheter 10. This requires the physician to either insert some type of device into catheter 10 to dislodge the blockage, or it requires the physician to completely remove catheter lO and insert another delivery catheter W096/22736 PCT~S96100221 into vessel 11. This is time consuming, cumbersome and inefficient.
FIG. 2 is a cross-sectional view of an embolization system 18 according to the present invention. Embolization system 18 includes delivery catheter 20, wire 22, occlusion particles 24, and pusher 26. Embolization system 18 is shown inserted within the lumen of a vessel 28.
In operation, delivery catheter 20 is typically inserted into vessel 28 and its distal end 30 is manipulated to access an occlusion site in vessel 28.
Particles 24 each have a wire receiving passageway 32 therein. Particles 24 are mounted onto wire 22 by inserting wire 22 through the wire receiving passageway 32 in particles 24. When a sufficient number of particles 24 are loaded onto wire 22, pusher 26 is also mounted onto wire 22. In a preferred embodiment, pusher 26 is a catheter, or other tube, having a lumen 34 therein for receiving wire 22. Pusher 26 has a distal end portion 36 which engages particles 24 as pusher 26 is advanced along wire 22. Wire 22, particles 24, and pusher 26 are all advanced within delivery catheter 20 to distal end 30 of delivery catheter 20, proximate the site to be occluded.
Wire 22 has a curved portion 38 at its distal end. The curved portion 38 is illustrated in FIG. 2 is a generally J-shaped or hook-shaped portion. Curved portion 38 serves to retain particles 24 on wire 22 until the treating physician desires to release a particle 24 from wire 22.
FIG. 3 illustrates the operation of embolization system 18 when the treating physician desires to release a particle 24 into vessel 28. When distal end 30 of delivery catheter 20 is positioned to - - -W096l22736 PCT~S96/00221 access a desired occlusion site in vessel 28, the treating physician advances pusher 26 along wire 22 until particles 24 engage curved portion 38 at the distal end of wire 22. The treating physician then continues to advance pusher 26 over wire 22 causing the distal most particle 24 to abut curved portion 38 of wire 22.
In the preferred embodiment, wire 22 is formed of a resilient, shape-memory material, such as a super elastic metal. Wire 22 can also be another suitable elongate member such as plastic (teflon) material or other resilient synthetic or natural material. Thus, as the treating physician continues to advance pusher 26, the distal most particle 24 causes curved portion 38 of wire 22 to straighten from its curved portion shown in phantom in FIG. 3, along a path generally indicated by arrow 40, to a straightened position shown in FIG. 3.
Once wire 22 is in the straightened position, the treating physician continues to advance pusher 26 until a desired number of particles 24 are released from wire 22 into vessel 28. When the treating physician has released a desired amount of particles 24 into vessel 28, the treating physician retracts pusher 26 along wire 22. This allows curved portion 38 of wire 22 to return to its original position (shown in phantom in FIG. 3).
Once in its original curved position, curved portion 38 of wire 22 again serves to retain additional particles 24 on wire 22.
Particles 24 are preferably radiopaque particles, such as platinum, making them visible under fluoroscopy. This allows the physician to achieve a high degree of control in releasing a desired number of particles 24 into vessel 28. When the desired number of particles 24 have been released, the treating physician W 096122736 PCTnUS96/00221 can very easily prevent additional particles 24 from being released by simply retracting pusher 26 on wire 22. Further, with the present invention, the treating physician can recover all particles 24 which are in delivery catheter 20 and which are still on wire 22.
Recovering such particles is extremely difficult in prior art embolization systems in which an injectate solution is used.
FIG. 4 is an enlarged cross-sectional view of embolization system 18 according to the present invention. FIG. 4 illustrates a number of preferred dimensions for items in embolization system 18. The inner diameter of particle 24 is designated by the letter A. The outer diameter of particle 24 is designated by the letter B. The length of particle 24 is designed by the letter C. The inner diameter of pusher 26 is designated by the letter D. The outer diameter of pusher 26 is designated by the letter E.
The inner diameter of delivery catheter 20 is designated by the letter F, and the outer diameter of delivery catheter 20 is designated by the letter G.
The inner diameter A of particle 24 is preferably just larger than the outer diameter of wire 22. For the purpose of the present invention, an occlusion particle 24 is defined as having an outer diameter B smaller than the inner diameter F of delivery catheter 20, an inner diameter A larger than the outer diameter of wire 22, and a length C less than approximately 1 cm. In the preferred embodiment, outer diameter B of particle 24 is preferably less than 0.75 mm. In another preferred embodiment, outer diameter B
of particle 24 is between 0.2 mm and 0.75 mm. Also, in the preferred embodiment, length C of particle 24 is less than approximately 1.2 mm. In another preferred W 096/22736 PCTn~r~,l00221 embodiment, length C of particle 24 is between 0.7 mm and 1.2 mm.
The inner diameter D of pusher 26 is larger than the outer diameter of wire 22, but must be smaller than the outer diameter B of particle 24. The outer diameter E of pusher 26 must be smaller than the inner diameter F of delivery catheter 20. In the preferred embodiment, delivery catheter 20 has an outer diameter G of 0.7 mm and an inner diameter F of 0.53 mm. In addition, pusher 26 has an outer diameter E of .33 mm and an inner diameter D of .15 mm. However, while these are preferred embodiments, and while the remainder of system 18 must be sized accordingly, any suitable dimensions can be used. It is also preferred that the inner diameter A of particle 24 is less than 3 mm.
It should be noted that any suitable method of mounting particles 24 onto wire 22 can be used. For instance, a single unitary piece can be mounted onto wire 22 and cut, or divided, into discrete particles 24.
In addition, the discrete particles 24 can first be formed and then mounted individually, or in groups, onto wire 22.
It should also be noted that while platinum is a preferred material for particles 24, other materials can be used. For instance, the present embolization system 18 can be used in conjunction with chemotherapeutic drugs. In that instance, it is beneficial to form particle 24 of radioisotope material which enhances the effectiveness of the chemotherapy, and which enhances the effectiveness of embolization on tumors. Also, the material of particle 24 can be a polymeric substance. Further, the density of the material used to form particle 24 will, in some instances, be determined based on the technique to be W096/22736 PCT~S96/00221 used. For example, the particles can be made of a material having a density greater than blood or less than blood, depending on the requirements for the particular vasculature being embolized.
The present invention overcomes certain problems associated with occlusions based on thrombus formation. If thrombus formation does form part of the occlusive effect of particles 24, and anti-coagulant therapy is used, the treating physician can easily release additional particles 24 to obtain desired occlusion. This can be carefully monitored and controlled so that substantially no reflux occurs.
The present invention also provides an efficient technique and apparatus for aligning particles 24 generally along a longitudinal axis of delivery catheter 20. Particles 24 cannot be released from wire 22 unless they are released at the distal end of wire 22, and then only when the treating physician advances pusher 26 to a sufficient extent to release the particles 24. This essentially precludes particles 24 from being dislodged within delivery catheter 20 at an undesirable position. Thus, delivery catheter 20 does not become blocked by particles 24 lodging against one another and the lumen walls of catheter 20.
It should also be noted that the J-shaped or hook-shaped distal end portion 38 of wire 22 allows the treating physician to release particles 24, but also helps to prevent intimal injury. Since the curved portion 38 is quite large and smoothly curved, it does not damage the interior surface of the vessel.
In addition, the controlled release of particles 24 accomplished by the present invention substantially reduces the incidence of reflux. Since the treating physician is capable of monitoring the W O 96/22736 P(~rnUS96/00221 precise amount of particles 24 released, that amount can be controlled and adjusted when distal flow is reduced due to partial occlusion of the vessel. This substantially eliminates problems associated with reflux.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
BACKGROUND OF THE INVENTION
The present invention relates to an embolization system to block flow through a selected portion of a lumen. More particularly, the present invention relates to a system for introducing occlusion particles into the lumen of a blood vessel.
Embolization techniques are currently used to treat a variety of vascular and non-vascular diseases.
Such diseases include arteriovenous malformations (AVMs), aneurysms, arteriovenous fistulas, and tumors.
There are currently three basic types of embolization systems in use. Those systems include embolic liquids, solid or solid-type agents, and particles.
Embolic liquids include glues, (polymerizing agents), alcohols, and precipitating agents. Typical examples of embolic liquids are n-butylcyanoacrylate (n-BCA), ethyl alcohol and a precipitating agent sold by Ethicon of Germany under the tradename Ethibloc. The glues used as embolic liquids typically act to polymerize and harden in the vessel, thereby blocking or occluding the vessel into which they are introduced.
The alcohol or alcohol derivatives cause tissue damage to the vessel with resulting thrombus formation for occlusion. Precipitating agents typically include a precipitating agent which is dissolved in infusion solution, but insoluble in a blood environment. When the infusion solution is introduced into the vessel, the precipitating agent precipitates out to cause occlusion.
Embolic liquids currently suffer from a number of disadvantages. One disadvantage is that the liquids lack radiopacity. This makes it difficult to monitor the administration of the embolic liquids. Another disadvantage is that the release of embolic liquids into W096/22736 PCT~S96/00221 the vessel to be occluded is difficult to control. The liquids must be released upstream of the site at which eventual occlusion is desired. Blood flow carries the embolizing li~uid through the lumen of the vessel, and it is difficult to control the release of a proper amount of occlusive liquid into the vessel to insure that occlusion occurs at the desired site in the vessel.
Solid agents, when used in an embolization system, conventionally include occluding articles which are more discrete in nature than embolic liquids. Such articles have typically been formed of suture material or coils which are introduced into the vessel. The suture material (often silk), once released, assumes a convoluted shape within the vessel to cause thrombus formation and occlusion. A suture material occlusion system is discussed in the ~itchart et al. U.S. Patent 4,994,069 issued February 19, 1991. Coils, or coil assemblies, used as solid occlusion agents are shown in the Sepetka U.S. Patent 5,234,437 issued August 10, 1993. The coils occlude the desired site in the vessel by posing a physical barrier to blood flow. This promotes thrombus formation at the desired site, which eventually occludes the vessel.
However, solid agents also suffer from a number of disadvantages. First, solid agents conventionally depend on thrombus formation in order to accomplish complete occlusion. However, if anti-coagulant agents are introduced into the bloodstream during surgery, the anticoagulant can substantially prevent thrombus formation thereby minimizing the occlusive effect of the solid agent. Additionally, the bodies~ natural clot dissolving factors can cause recanalization. Further, when the solid agent is a coil, it is either an insertion coil or a detachable W096/22736 PCT~S96/00221 coil. Insertion coils are introduced into the vessel by injection, or by being pushed through a base catheter.
Once introduced into the vessel, they can become irretrievable and accurate delivery is difficult to control. When the coil is detachable, it must be particularly sized to fit the lumen of the vessel at the desired occlusion site. However, the size of the lumen of the vessel is difficult to predict. Therefore, it is not uncommon for the treating physician to move the solid agent (detachable coil) to the occlusion site only to find out that the dimensions of the detachable coil are inappropriate to the occlusion site in the vessel.
This requires the physician to remove essentially the entire coil system and to re-insert the system with a different size detachable coil. It may be necessary to repeat this process a number of times before the properly sized solid agent is finally inserted in the lumen. Also, when removing an improperly sized detachable coil, it is not uncommon for the coil to engage the base catheter and unravel or unwind. Such a system is time consuming and inefficient.
A third conventional embolization system utilizes what are known as embolizing particles or occlusion particles. Embolizing particles are typically smaller than solid occlusion agents and are suspended in solution. The solution is injected into the lumen to be occluded through a catheter. Typical embolization particles are made of polyvinylalcohol (PVA). The polyvinylalcohol particles are formed of a ground block of material which is put through a series of sieves to segregate the particles into various size categories.
The particles are suspended in solution and injected into the vessel through a delivery catheter.
W O 96/22736 P(~rrUS96/00221 However, conventional embolizing particles also suffer from a number of disadvantages. For example, in conventional systems, the particles cannot be easily retrieved once they are injected into the vessel. In addition, it is very difficult to control precisely how much of the injectate is delivered.
Further, typical PVA particles are in suspension and are therefore not typically well aligned as they travel through the catheter. Therefore, they can wedge together and substantially block the delivery catheter.
This requires the treating physician to either remove the entire system, including the delivery catheter, and replace it with another system, or to take extra time to remove the blockage from the delivery catheter. Another major problem associated with injecting PVA particles to occlude a vessel is referred to as reflux. Essentially, as PVA is injected into the vessel, and as the vessel begins to close, the distal flow at the occlusion site becomes smaller. Therefore, less injectate is needed at the occlusion site. If too much solution is injected, and the distal flow cannot accommodate the extra injectate, then the flow becomes proximal and can occlude a lumen of a normal vessel at a proximal site.
This problem essentially arises from the difficulty in controlling the amount of PVA particles injected into the vessel.
SU~ ARY OF THE IN VEN TION
An embolization system includes a catheter having a lumen. An elongate member is insertable within the lumen of the catheter. An occlusion particle has a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle through the lumen of the catheter and into a vessel.
W096l22736 PCT~S96/00221 BRIEF DESCRIPTION OF THE DRAWINGS
FIGs. 1, lA and lB illustrate one common problem with prior art embolization systems.
FIG. 2 is a cross-sectional view of an embolization system according to the present invention.
FIG. 3 is a cross-sectional view of the embolization system shown in FIG. 2, illustrating delivery of an occlusion particle into a vessel.
FIG. 4 is an enlarged and more detailed cross-section of the embolization system shown in FIGS. 2 and3.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
FIGS. 1, lA and lB illustrate a common problem with polyvinylalcohol (PVA) injection type embolization systems. FIG. 1 shows a delivery catheter 10 residing in a vessel 11 and having a distal end 13. Catheter 10 is carrying a PVA solution, or injectate, which includes a plurality of PVA particles 12. While PVA particles 12 are not typically perfect spheres, they are illustrated as spheres for the sake of simplicity in FIG. 1. In operation, delivery catheter 10 is typically manipulated through vessel 11 so distal end 13 is proximate a desired occlusion site 14. When distal end 13 of delivery catheter 10 reaches occlusion site 14, the solution carrying PVA particles 12 is injected into the delivery catheter 10 and delivered to occlusion site 14.
It is difficult to predict the precise amount (both size of particles and number of particles required) of injectate needed to occlude vessel 11 at site 14. Also, it is difficult to precisely control the amount of injectate delivered to site 14. This results in a wide variety of problems, most of which were mentioned in the Background of the Invention portion of the present specification.
W 096/22736 PCTnUS96/00221 In addition, PVA-type occlusion can also suffer from one of the problems commonly associated with discrete or solid-type occlusion devices. When the PVA
particles 12 are delivered to site 14, thrombus formation can cause occlusion. However, during surgery, anticoagulant therapy may be administered. This therapy can substantially prevent thrombus formation. Thus, the treating physician must inject more solution carrying PVA particles 12. Due to the difficulty in controlling delivery of an accurate amount (size and number of particles) of the solution, the need to deliver extra solution exacerbates the problem of potential reflux in vessel 11. Further, the body has natural clot dissolving factors which can begin to act on the thrombus. This can cause the thrombus at site 14 to dissolve over time.
In accessing site 14, catheter 10 must commonly make a number of bends. FIG. lA, taken along section lines lA-lA in FIG. 1, shows the conventional cross-section of catheter 10 as being circular.
However, FIG. lB is taken along section lines lB-lB of FIG. 1 at a point where catheter 10 bends to access site 14. The cross-section at the bent portion of catheter 10 is oval shaped. Since particles 12 are simply mixed in solution and injected through catheter 10, they are not typically aligned along a longitudinal axis of catheter 10. As the particles reach the oval cross-section of catheter 10, it is not uncommon for the particles to lodge against one another and the walls of catheter 10 to obstruct flow of the solution through catheter 10. This requires the physician to either insert some type of device into catheter 10 to dislodge the blockage, or it requires the physician to completely remove catheter lO and insert another delivery catheter W096/22736 PCT~S96100221 into vessel 11. This is time consuming, cumbersome and inefficient.
FIG. 2 is a cross-sectional view of an embolization system 18 according to the present invention. Embolization system 18 includes delivery catheter 20, wire 22, occlusion particles 24, and pusher 26. Embolization system 18 is shown inserted within the lumen of a vessel 28.
In operation, delivery catheter 20 is typically inserted into vessel 28 and its distal end 30 is manipulated to access an occlusion site in vessel 28.
Particles 24 each have a wire receiving passageway 32 therein. Particles 24 are mounted onto wire 22 by inserting wire 22 through the wire receiving passageway 32 in particles 24. When a sufficient number of particles 24 are loaded onto wire 22, pusher 26 is also mounted onto wire 22. In a preferred embodiment, pusher 26 is a catheter, or other tube, having a lumen 34 therein for receiving wire 22. Pusher 26 has a distal end portion 36 which engages particles 24 as pusher 26 is advanced along wire 22. Wire 22, particles 24, and pusher 26 are all advanced within delivery catheter 20 to distal end 30 of delivery catheter 20, proximate the site to be occluded.
Wire 22 has a curved portion 38 at its distal end. The curved portion 38 is illustrated in FIG. 2 is a generally J-shaped or hook-shaped portion. Curved portion 38 serves to retain particles 24 on wire 22 until the treating physician desires to release a particle 24 from wire 22.
FIG. 3 illustrates the operation of embolization system 18 when the treating physician desires to release a particle 24 into vessel 28. When distal end 30 of delivery catheter 20 is positioned to - - -W096l22736 PCT~S96/00221 access a desired occlusion site in vessel 28, the treating physician advances pusher 26 along wire 22 until particles 24 engage curved portion 38 at the distal end of wire 22. The treating physician then continues to advance pusher 26 over wire 22 causing the distal most particle 24 to abut curved portion 38 of wire 22.
In the preferred embodiment, wire 22 is formed of a resilient, shape-memory material, such as a super elastic metal. Wire 22 can also be another suitable elongate member such as plastic (teflon) material or other resilient synthetic or natural material. Thus, as the treating physician continues to advance pusher 26, the distal most particle 24 causes curved portion 38 of wire 22 to straighten from its curved portion shown in phantom in FIG. 3, along a path generally indicated by arrow 40, to a straightened position shown in FIG. 3.
Once wire 22 is in the straightened position, the treating physician continues to advance pusher 26 until a desired number of particles 24 are released from wire 22 into vessel 28. When the treating physician has released a desired amount of particles 24 into vessel 28, the treating physician retracts pusher 26 along wire 22. This allows curved portion 38 of wire 22 to return to its original position (shown in phantom in FIG. 3).
Once in its original curved position, curved portion 38 of wire 22 again serves to retain additional particles 24 on wire 22.
Particles 24 are preferably radiopaque particles, such as platinum, making them visible under fluoroscopy. This allows the physician to achieve a high degree of control in releasing a desired number of particles 24 into vessel 28. When the desired number of particles 24 have been released, the treating physician W 096122736 PCTnUS96/00221 can very easily prevent additional particles 24 from being released by simply retracting pusher 26 on wire 22. Further, with the present invention, the treating physician can recover all particles 24 which are in delivery catheter 20 and which are still on wire 22.
Recovering such particles is extremely difficult in prior art embolization systems in which an injectate solution is used.
FIG. 4 is an enlarged cross-sectional view of embolization system 18 according to the present invention. FIG. 4 illustrates a number of preferred dimensions for items in embolization system 18. The inner diameter of particle 24 is designated by the letter A. The outer diameter of particle 24 is designated by the letter B. The length of particle 24 is designed by the letter C. The inner diameter of pusher 26 is designated by the letter D. The outer diameter of pusher 26 is designated by the letter E.
The inner diameter of delivery catheter 20 is designated by the letter F, and the outer diameter of delivery catheter 20 is designated by the letter G.
The inner diameter A of particle 24 is preferably just larger than the outer diameter of wire 22. For the purpose of the present invention, an occlusion particle 24 is defined as having an outer diameter B smaller than the inner diameter F of delivery catheter 20, an inner diameter A larger than the outer diameter of wire 22, and a length C less than approximately 1 cm. In the preferred embodiment, outer diameter B of particle 24 is preferably less than 0.75 mm. In another preferred embodiment, outer diameter B
of particle 24 is between 0.2 mm and 0.75 mm. Also, in the preferred embodiment, length C of particle 24 is less than approximately 1.2 mm. In another preferred W 096/22736 PCTn~r~,l00221 embodiment, length C of particle 24 is between 0.7 mm and 1.2 mm.
The inner diameter D of pusher 26 is larger than the outer diameter of wire 22, but must be smaller than the outer diameter B of particle 24. The outer diameter E of pusher 26 must be smaller than the inner diameter F of delivery catheter 20. In the preferred embodiment, delivery catheter 20 has an outer diameter G of 0.7 mm and an inner diameter F of 0.53 mm. In addition, pusher 26 has an outer diameter E of .33 mm and an inner diameter D of .15 mm. However, while these are preferred embodiments, and while the remainder of system 18 must be sized accordingly, any suitable dimensions can be used. It is also preferred that the inner diameter A of particle 24 is less than 3 mm.
It should be noted that any suitable method of mounting particles 24 onto wire 22 can be used. For instance, a single unitary piece can be mounted onto wire 22 and cut, or divided, into discrete particles 24.
In addition, the discrete particles 24 can first be formed and then mounted individually, or in groups, onto wire 22.
It should also be noted that while platinum is a preferred material for particles 24, other materials can be used. For instance, the present embolization system 18 can be used in conjunction with chemotherapeutic drugs. In that instance, it is beneficial to form particle 24 of radioisotope material which enhances the effectiveness of the chemotherapy, and which enhances the effectiveness of embolization on tumors. Also, the material of particle 24 can be a polymeric substance. Further, the density of the material used to form particle 24 will, in some instances, be determined based on the technique to be W096/22736 PCT~S96/00221 used. For example, the particles can be made of a material having a density greater than blood or less than blood, depending on the requirements for the particular vasculature being embolized.
The present invention overcomes certain problems associated with occlusions based on thrombus formation. If thrombus formation does form part of the occlusive effect of particles 24, and anti-coagulant therapy is used, the treating physician can easily release additional particles 24 to obtain desired occlusion. This can be carefully monitored and controlled so that substantially no reflux occurs.
The present invention also provides an efficient technique and apparatus for aligning particles 24 generally along a longitudinal axis of delivery catheter 20. Particles 24 cannot be released from wire 22 unless they are released at the distal end of wire 22, and then only when the treating physician advances pusher 26 to a sufficient extent to release the particles 24. This essentially precludes particles 24 from being dislodged within delivery catheter 20 at an undesirable position. Thus, delivery catheter 20 does not become blocked by particles 24 lodging against one another and the lumen walls of catheter 20.
It should also be noted that the J-shaped or hook-shaped distal end portion 38 of wire 22 allows the treating physician to release particles 24, but also helps to prevent intimal injury. Since the curved portion 38 is quite large and smoothly curved, it does not damage the interior surface of the vessel.
In addition, the controlled release of particles 24 accomplished by the present invention substantially reduces the incidence of reflux. Since the treating physician is capable of monitoring the W O 96/22736 P(~rnUS96/00221 precise amount of particles 24 released, that amount can be controlled and adjusted when distal flow is reduced due to partial occlusion of the vessel. This substantially eliminates problems associated with reflux.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
Claims (10)
1. An embolization system including a catheter having a lumen, and characterized by:
an elongate member, insertable within the lumen of the catheter; and an occlusion particle having a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle.
an elongate member, insertable within the lumen of the catheter; and an occlusion particle having a receiving passageway therein for receiving the elongate member so the elongate member guides movement of the occlusion particle.
2. The embolization system of claim 1 wherein the embolization system further comprises:
a pusher, slidable relative to the elongate member within the lumen of the catheter to engage the occlusion particle and to move the occlusion particle relative to the elongate member.
a pusher, slidable relative to the elongate member within the lumen of the catheter to engage the occlusion particle and to move the occlusion particle relative to the elongate member.
3. The embolization system of claim 2 wherein the pusher comprises:
a second elongate member having a receiving passageway so the pusher is slidable along the elongate member, the elongate member moving relative to the pusher within the receiving passageway.
a second elongate member having a receiving passageway so the pusher is slidable along the elongate member, the elongate member moving relative to the pusher within the receiving passageway.
4. The embolization system of claim 3 wherein the elongate member comprises a wire and wherein the pusher comprises:
a tube having a lumen, the lumen sized large enough to slidably receive the wire and sized smaller than an outer dimension of the occlusion particle.
a tube having a lumen, the lumen sized large enough to slidably receive the wire and sized smaller than an outer dimension of the occlusion particle.
5. The embolization system of claim 4 wherein the pusher has a distal end portion for engaging the occlusion particles and pushing the occlusion particle along the wire so that the occlusion particle slides relative to the wire, the wire passing through the wire receiving passageway in the occlusion particle.
6. The embolization system of claim 5 wherein the slide receiving passageway comprises a bore defined by the occlusion particle, the bore being large enough to slidably receive the wire.
7. The embolization system of claim 1 wherein the occlusion particle is formed of radiopaque material.
8. The embolization system of claim 2 wherein the elongate member comprises:
a retaining end portion for controllably retaining the occlusion particle on the elongate member.
a retaining end portion for controllably retaining the occlusion particle on the elongate member.
9. The embolization system of claim 8 wherein the elongate member comprises a wire and wherein the retaining end portion comprises:
a curved portion of the wire located generally at the distal end of the wire.
a curved portion of the wire located generally at the distal end of the wire.
10. The embolization system of claim 9 wherein the wire comprises:
a flexible shape memory material, the curved portion being flexible to release the occlusion particle and return to its curved shape.
a flexible shape memory material, the curved portion being flexible to release the occlusion particle and return to its curved shape.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37880895A | 1995-01-27 | 1995-01-27 | |
| US08/378,808 | 1995-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2207667A1 true CA2207667A1 (en) | 1996-08-01 |
Family
ID=23494628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002207667A Abandoned CA2207667A1 (en) | 1995-01-27 | 1996-01-03 | Embolizing system |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US5895411A (en) |
| EP (1) | EP0805656B1 (en) |
| JP (1) | JP3625837B2 (en) |
| CA (1) | CA2207667A1 (en) |
| DE (1) | DE69632392T2 (en) |
| WO (1) | WO1996022736A1 (en) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083220A (en) | 1990-03-13 | 2000-07-04 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
| USRE42625E1 (en) | 1990-03-13 | 2011-08-16 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
| USRE41029E1 (en) | 1990-03-13 | 2009-12-01 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
| US5814062A (en) | 1994-12-22 | 1998-09-29 | Target Therapeutics, Inc. | Implant delivery assembly with expandable coupling/decoupling mechanism |
| US6994689B1 (en) | 1995-06-05 | 2006-02-07 | Medtronic Vascular, Inc. | Occlusion of a vessel |
| US6312407B1 (en) | 1995-06-05 | 2001-11-06 | Medtronic Percusurge, Inc. | Occlusion of a vessel |
| AU733332B2 (en) | 1996-02-02 | 2001-05-10 | Transvascular, Inc. | Methods and apparatus for blocking flow through blood vessels |
| EP0951870A1 (en) * | 1998-04-21 | 1999-10-27 | Medicorp S.A. | Device for aneurysma treatment |
| US6511492B1 (en) * | 1998-05-01 | 2003-01-28 | Microvention, Inc. | Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders |
| FR2784580B1 (en) * | 1998-10-16 | 2004-06-25 | Biosepra Inc | POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME |
| US6333020B1 (en) | 1999-05-13 | 2001-12-25 | Micro Therapeutics, Inc. | Methods for treating AVM's using radio active compositions |
| US6602261B2 (en) | 1999-10-04 | 2003-08-05 | Microvention, Inc. | Filamentous embolic device with expansile elements |
| US6238403B1 (en) | 1999-10-04 | 2001-05-29 | Microvention, Inc. | Filamentous embolic device with expansible elements |
| US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| US8697137B2 (en) | 2000-03-24 | 2014-04-15 | Biosphere Medical, Inc. | Methods of using microspheres for active embolization |
| US7033374B2 (en) * | 2000-09-26 | 2006-04-25 | Microvention, Inc. | Microcoil vaso-occlusive device with multi-axis secondary configuration |
| US6890343B2 (en) * | 2000-12-14 | 2005-05-10 | Ensure Medical, Inc. | Plug with detachable guidewire element and methods for use |
| US6846319B2 (en) * | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
| US6896692B2 (en) | 2000-12-14 | 2005-05-24 | Ensure Medical, Inc. | Plug with collet and apparatus and method for delivering such plugs |
| US6623509B2 (en) * | 2000-12-14 | 2003-09-23 | Core Medical, Inc. | Apparatus and methods for sealing vascular punctures |
| US8083768B2 (en) | 2000-12-14 | 2011-12-27 | Ensure Medical, Inc. | Vascular plug having composite construction |
| EP2319430B1 (en) * | 2001-05-29 | 2013-11-13 | Microvention, Inc. | Vascular embolization device and method of manufacture |
| US20030014075A1 (en) * | 2001-07-16 | 2003-01-16 | Microvention, Inc. | Methods, materials and apparatus for deterring or preventing endoleaks following endovascular graft implanation |
| US6911219B2 (en) * | 2001-09-27 | 2005-06-28 | Surgica Corporation | Partially acetalized polyvinyl alcohol embolization particles, compositions containing those particles and methods of making and using them |
| US7131997B2 (en) * | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7094369B2 (en) * | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7053134B2 (en) * | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| US20030204246A1 (en) * | 2002-04-25 | 2003-10-30 | Jack Chu | Aneurysm treatment system and method |
| WO2003105917A2 (en) * | 2002-06-12 | 2003-12-24 | Scimed Life Systems, Inc. | Bulking agents |
| CN101919722A (en) | 2002-07-31 | 2010-12-22 | 微温森公司 | The vascular occluding device of three-part coaxial |
| US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7449236B2 (en) * | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7588825B2 (en) * | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| DE10259411A1 (en) * | 2002-12-19 | 2004-07-08 | Forschungszentrum Karlsruhe Gmbh | Medical clip and device for applying such a device |
| US7655048B2 (en) * | 2003-04-02 | 2010-02-02 | Furlow Jr Leonard T | Materials and methods for soft tissue augmentation |
| US9861346B2 (en) | 2003-07-14 | 2018-01-09 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
| ES2436596T3 (en) | 2003-07-14 | 2014-01-03 | W.L. Gore & Associates, Inc. | Oval foramen tubular permeable closure device (FOP) with retention system |
| US8480706B2 (en) | 2003-07-14 | 2013-07-09 | W.L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
| US20050013870A1 (en) * | 2003-07-17 | 2005-01-20 | Toby Freyman | Decellularized extracellular matrix of conditioned body tissues and uses thereof |
| US7976823B2 (en) * | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US8852229B2 (en) * | 2003-10-17 | 2014-10-07 | Cordis Corporation | Locator and closure device and method of use |
| US7361183B2 (en) * | 2003-10-17 | 2008-04-22 | Ensure Medical, Inc. | Locator and delivery device and method of use |
| US7901770B2 (en) * | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7736671B2 (en) * | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US20050238870A1 (en) * | 2004-04-22 | 2005-10-27 | Marcia Buiser | Embolization |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US20060025802A1 (en) * | 2004-07-30 | 2006-02-02 | Sowers William W | Embolic coil delivery system with U-shaped fiber release mechanism |
| US7918872B2 (en) * | 2004-07-30 | 2011-04-05 | Codman & Shurtleff, Inc. | Embolic device delivery system with retractable partially coiled-fiber release |
| US20060025801A1 (en) * | 2004-07-30 | 2006-02-02 | Robert Lulo | Embolic device deployment system with filament release |
| US7879064B2 (en) | 2004-09-22 | 2011-02-01 | Micro Therapeutics, Inc. | Medical implant |
| EP1793743B1 (en) | 2004-09-22 | 2009-11-18 | Dendron GmbH | Micro-spiral implantation device |
| US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7727555B2 (en) * | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7858183B2 (en) * | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) * | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US8088144B2 (en) * | 2005-05-04 | 2012-01-03 | Ensure Medical, Inc. | Locator and closure device and method of use |
| US7674271B2 (en) * | 2005-05-04 | 2010-03-09 | InTailor Surgical, Inc. | Endoluminal gastric ring and method |
| US8926654B2 (en) | 2005-05-04 | 2015-01-06 | Cordis Corporation | Locator and closure device and method of use |
| KR101429774B1 (en) | 2005-05-09 | 2014-10-02 | 바이오스피어 메디칼 에스.에이. | Compositions and methods using microspheres and non-ionic contrast agents |
| US7708754B2 (en) | 2005-06-02 | 2010-05-04 | Codman & Shurtleff, Pc | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US7811305B2 (en) * | 2005-06-02 | 2010-10-12 | Codman & Shurtleff, Inc. | Stretch resistant embolic coil delivery system with spring release mechanism |
| US7377932B2 (en) * | 2005-06-02 | 2008-05-27 | Cordis Neurovascular, Inc. | Embolic coil delivery system with mechanical release mechanism |
| US7367987B2 (en) * | 2005-06-02 | 2008-05-06 | Cordis Neurovascular, Inc. | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US7985238B2 (en) * | 2005-06-02 | 2011-07-26 | Codman & Shurtleff, Inc. | Embolic coil delivery system with spring wire release mechanism |
| US7819892B2 (en) | 2005-06-02 | 2010-10-26 | Codman & Shurtleff, Inc. | Embolic coil delivery system with spring wire release mechanism |
| US20060276833A1 (en) * | 2005-06-02 | 2006-12-07 | Keith Balgobin | Stretch resistant embolic coil delivery system with spring assisted release mechanism |
| US7819891B2 (en) * | 2005-06-02 | 2010-10-26 | Codman & Shurtleff, Inc. | Stretch resistant embolic coil delivery system with spring release mechanism |
| US7708755B2 (en) * | 2005-06-02 | 2010-05-04 | Codman & Shurtleff Inc. | Stretch resistant embolic coil delivery system with combined mechanical and pressure release mechanism |
| US7799052B2 (en) * | 2005-06-02 | 2010-09-21 | Codman & Shurtleff, Inc. | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US20060276830A1 (en) * | 2005-06-02 | 2006-12-07 | Keith Balgobin | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US20060276825A1 (en) * | 2005-06-02 | 2006-12-07 | Vladimir Mitelberg | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US7371251B2 (en) * | 2005-06-02 | 2008-05-13 | Cordis Neurovascular, Inc. | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US7371252B2 (en) | 2005-06-02 | 2008-05-13 | Cordis Neurovascular, Inc. | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US20060276827A1 (en) * | 2005-06-02 | 2006-12-07 | Vladimir Mitelberg | Stretch resistant embolic coil delivery system with mechanical release mechanism |
| US20070004973A1 (en) * | 2005-06-15 | 2007-01-04 | Tan Sharon M L | Tissue treatment methods |
| US9463426B2 (en) * | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| JP4243268B2 (en) * | 2005-09-07 | 2009-03-25 | アドバンスド・マスク・インスペクション・テクノロジー株式会社 | Pattern inspection apparatus and pattern inspection method |
| US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
| EP1959873B1 (en) | 2005-12-13 | 2015-05-20 | Codman & Shurtleff, Inc. | Detachment actuator for use with medical device deployment systems |
| US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
| US20070142859A1 (en) * | 2005-12-19 | 2007-06-21 | Boston Scientific Scimed, Inc. | Embolic coils |
| US8152839B2 (en) * | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7947368B2 (en) * | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US7501179B2 (en) * | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US20070142560A1 (en) * | 2005-12-21 | 2007-06-21 | Young-Ho Song | Block copolymer particles |
| WO2007090127A2 (en) | 2006-01-30 | 2007-08-09 | Surgica Corporation | Compressible intravascular embolization particles and related methods and delivery systems |
| WO2007090130A2 (en) * | 2006-01-30 | 2007-08-09 | Surgica Corporation | Porous intravascular embolization particles and related methods |
| US7691124B2 (en) * | 2006-01-31 | 2010-04-06 | Codman & Shurtleff, Inc. | Delivery of therapeutic devices |
| US7942894B2 (en) * | 2006-01-31 | 2011-05-17 | Codman & Shurtleff, Inc. | Embolic device delivery system |
| US20070178137A1 (en) * | 2006-02-01 | 2007-08-02 | Toby Freyman | Local control of inflammation |
| US8551135B2 (en) * | 2006-03-31 | 2013-10-08 | W.L. Gore & Associates, Inc. | Screw catch mechanism for PFO occluder and method of use |
| JP5230602B2 (en) | 2006-04-17 | 2013-07-10 | タイコ ヘルスケア グループ リミテッド パートナーシップ | System and method for mechanically positioning an endovascular implant |
| US8777979B2 (en) | 2006-04-17 | 2014-07-15 | Covidien Lp | System and method for mechanically positioning intravascular implants |
| BRPI0711784B8 (en) | 2006-06-15 | 2021-06-22 | Microvention Inc | embolization device constructed of expandable polymer and its method of preparation |
| US20070299461A1 (en) * | 2006-06-21 | 2007-12-27 | Boston Scientific Scimed, Inc. | Embolic coils and related components, systems, and methods |
| US8366720B2 (en) | 2006-07-31 | 2013-02-05 | Codman & Shurtleff, Inc. | Interventional medical device system having an elongation retarding portion and method of using the same |
| US8062325B2 (en) | 2006-07-31 | 2011-11-22 | Codman & Shurtleff, Inc. | Implantable medical device detachment system and methods of using the same |
| US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
| US20080145658A1 (en) * | 2006-12-15 | 2008-06-19 | Boston Scientific Scimed, Inc. | Freeze Thaw Methods For Making Polymer Particles |
| KR20100015521A (en) | 2007-03-13 | 2010-02-12 | 마이크로 테라퓨틱스 인코포레이티드 | An implant, a mandrel, and a method of forming an implant |
| JP5249249B2 (en) | 2007-03-13 | 2013-07-31 | コヴィディエン リミテッド パートナーシップ | Implant including a coil and a stretch resistant member |
| US9005242B2 (en) | 2007-04-05 | 2015-04-14 | W.L. Gore & Associates, Inc. | Septal closure device with centering mechanism |
| CN101842061A (en) | 2007-06-25 | 2010-09-22 | 微排放器公司 | Self-expanding prosthesis |
| CA2709379C (en) | 2007-12-21 | 2016-08-16 | Microvention, Inc. | Hydrogel filaments for biomedical uses |
| US20130165967A1 (en) | 2008-03-07 | 2013-06-27 | W.L. Gore & Associates, Inc. | Heart occlusion devices |
| US20110212179A1 (en) * | 2008-10-30 | 2011-09-01 | David Liu | Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same |
| US10639396B2 (en) | 2015-06-11 | 2020-05-05 | Microvention, Inc. | Polymers |
| US20120029556A1 (en) | 2009-06-22 | 2012-02-02 | Masters Steven J | Sealing device and delivery system |
| US8956389B2 (en) | 2009-06-22 | 2015-02-17 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
| JP2013505791A (en) * | 2009-09-24 | 2013-02-21 | マイクロベンション インコーポレイテッド | Injectable hydrogel fiber for medical use |
| KR101745748B1 (en) * | 2009-10-26 | 2017-06-12 | 마이크로벤션, 인코포레이티드 | Embolization device constructed from expansile polymer |
| US9456823B2 (en) | 2011-04-18 | 2016-10-04 | Terumo Corporation | Embolic devices |
| US9770232B2 (en) | 2011-08-12 | 2017-09-26 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
| US9579104B2 (en) | 2011-11-30 | 2017-02-28 | Covidien Lp | Positioning and detaching implants |
| US9011480B2 (en) | 2012-01-20 | 2015-04-21 | Covidien Lp | Aneurysm treatment coils |
| US9687245B2 (en) | 2012-03-23 | 2017-06-27 | Covidien Lp | Occlusive devices and methods of use |
| WO2013158781A1 (en) | 2012-04-18 | 2013-10-24 | Microvention, Inc. | Embolic devices |
| US10828019B2 (en) | 2013-01-18 | 2020-11-10 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
| US9662120B2 (en) | 2013-08-23 | 2017-05-30 | Cook Medical Technologies Llc | Detachable treatment device delivery system utilizing compression at attachment zone |
| WO2015153996A1 (en) | 2014-04-03 | 2015-10-08 | Micro Vention, Inc. | Embolic devices |
| US9713475B2 (en) | 2014-04-18 | 2017-07-25 | Covidien Lp | Embolic medical devices |
| US10092663B2 (en) | 2014-04-29 | 2018-10-09 | Terumo Corporation | Polymers |
| JP6599361B2 (en) | 2014-04-29 | 2019-10-30 | マイクロベンション インコーポレイテッド | Polymer containing an active agent |
| US9808230B2 (en) | 2014-06-06 | 2017-11-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
| CN110612096A (en) * | 2017-03-27 | 2019-12-24 | 苏州医本生命科技有限公司 | Chain medicine structure and preparation facilities and storage device thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE233303C (en) * | 1911-04-05 | |||
| US3921632A (en) * | 1974-08-16 | 1975-11-25 | Frank M Bardani | Implant device |
| US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
| DD233303A1 (en) * | 1984-12-28 | 1986-02-26 | Univ Berlin Humboldt | CLOSURE BODY FOR BLOOD OBJECTS AND METHOD FOR ITS INTRODUCTION |
| US4708718A (en) * | 1985-07-02 | 1987-11-24 | Target Therapeutics | Hyperthermic treatment of tumors |
| US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
| FR2641692A1 (en) * | 1989-01-17 | 1990-07-20 | Nippon Zeon Co | Plug for closing an opening for a medical application, and device for the closure plug making use thereof |
| US5354295A (en) * | 1990-03-13 | 1994-10-11 | Target Therapeutics, Inc. | In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
| US5021059A (en) * | 1990-05-07 | 1991-06-04 | Kensey Nash Corporation | Plug device with pulley for sealing punctures in tissue and methods of use |
| US5342394A (en) * | 1990-05-16 | 1994-08-30 | Olympus Optical Co., Ltd. | Apparatus for blocking a vein branch and method of blocking a vein branch |
| JP2514087Y2 (en) * | 1990-05-25 | 1996-10-16 | 幸三 牧田 | Balloon with detachable double-sided check valve |
| US5108407A (en) * | 1990-06-08 | 1992-04-28 | Rush-Presbyterian St. Luke's Medical Center | Method and apparatus for placement of an embolic coil |
| US5167624A (en) * | 1990-11-09 | 1992-12-01 | Catheter Research, Inc. | Embolus delivery system and method |
| US5226911A (en) * | 1991-10-02 | 1993-07-13 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
| US5256146A (en) * | 1991-10-11 | 1993-10-26 | W. D. Ensminger | Vascular catheterization system with catheter anchoring feature |
| US5290310A (en) * | 1991-10-30 | 1994-03-01 | Howmedica, Inc. | Hemostatic implant introducer |
| US5411520A (en) * | 1991-11-08 | 1995-05-02 | Kensey Nash Corporation | Hemostatic vessel puncture closure system utilizing a plug located within the puncture tract spaced from the vessel, and method of use |
| US5261916A (en) * | 1991-12-12 | 1993-11-16 | Target Therapeutics | Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling |
| ATE187053T1 (en) * | 1991-12-12 | 1999-12-15 | Target Therapeutics Inc | UNCOUPLING, SLIDING, VESSEL-OCCLOSING SPIRAL WITH INTERLOCKING COUPLING ELEMENTS |
| US5234437A (en) * | 1991-12-12 | 1993-08-10 | Target Therapeutics, Inc. | Detachable pusher-vasoocclusion coil assembly with threaded coupling |
| US5263964A (en) * | 1992-05-06 | 1993-11-23 | Coil Partners Ltd. | Coaxial traction detachment apparatus and method |
| US5292332A (en) * | 1992-07-27 | 1994-03-08 | Lee Benjamin I | Methods and device for percutanceous sealing of arterial puncture sites |
| US5250071A (en) * | 1992-09-22 | 1993-10-05 | Target Therapeutics, Inc. | Detachable embolic coil assembly using interlocking clasps and method of use |
| US5350397A (en) * | 1992-11-13 | 1994-09-27 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
| US5312415A (en) * | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
| IL106946A0 (en) * | 1992-09-22 | 1993-12-28 | Target Therapeutics Inc | Detachable embolic coil assembly |
| US5334216A (en) * | 1992-12-10 | 1994-08-02 | Howmedica Inc. | Hemostatic plug |
| US5320639A (en) * | 1993-03-12 | 1994-06-14 | Meadox Medicals, Inc. | Vascular plug delivery system |
-
1996
- 1996-01-03 CA CA002207667A patent/CA2207667A1/en not_active Abandoned
- 1996-01-03 WO PCT/US1996/000221 patent/WO1996022736A1/en active IP Right Grant
- 1996-01-03 EP EP96902111A patent/EP0805656B1/en not_active Expired - Lifetime
- 1996-01-03 JP JP52287396A patent/JP3625837B2/en not_active Expired - Fee Related
- 1996-01-03 DE DE69632392T patent/DE69632392T2/en not_active Expired - Fee Related
-
1997
- 1997-05-19 US US08/858,519 patent/US5895411A/en not_active Expired - Lifetime
- 1997-09-18 US US08/933,267 patent/US5891155A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69632392T2 (en) | 2004-09-16 |
| JP3625837B2 (en) | 2005-03-02 |
| DE69632392D1 (en) | 2004-06-09 |
| US5891155A (en) | 1999-04-06 |
| EP0805656A1 (en) | 1997-11-12 |
| WO1996022736A1 (en) | 1996-08-01 |
| US5895411A (en) | 1999-04-20 |
| EP0805656B1 (en) | 2004-05-06 |
| JPH11503334A (en) | 1999-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5895411A (en) | Embolizing system | |
| US5443478A (en) | Multi-element intravascular occlusion device | |
| EP1207791B1 (en) | Controlled injection of liquid embolic composition | |
| AU741804B2 (en) | Vasoocclusive device including asymmetrical pluralities of fibers | |
| JP3856841B2 (en) | Embolization device for placement in blood vessels | |
| EP0865772B1 (en) | Catheter deliverable thrombogenic apparatus | |
| EP1105180B1 (en) | Apparatus for intraluminal deposition of hydrogels | |
| US20040111112A1 (en) | Method and apparatus for retaining embolic material | |
| US20040172056A1 (en) | Bifurcated aneurysm buttress arrangement | |
| US20080058724A1 (en) | Method and system for delivering an implant utilizing a lumen reducing member | |
| US10517605B2 (en) | Embolic device, an apparatus for embolizing a target vascular site and a method thereof | |
| WO1999011191A1 (en) | System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber | |
| JP2003511188A (en) | Filamentary embolic device with expansion element | |
| CN115670566A (en) | Related systems and methods for vessel occlusion | |
| EP1169969A1 (en) | Pedicle occlusion device | |
| US20060085028A1 (en) | Vessel occlusion system | |
| EP1345556B1 (en) | Occlusion device | |
| WO2007033375A2 (en) | Methods and devices for drug eluding embolization | |
| Bilbao et al. | Platinum Wire Emholization of an Intrahepatic Arterioportal Fistula. | |
| Herrmann et al. | Interventional radiological procedures in impaired function of surgically implanted catheter-port systems | |
| Rome et al. | Defect closure—coil embolization | |
| Tuite et al. | Coils, Occluders, and Plugs | |
| Thomas et al. | Endovascular Approaches and Techniques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |